Form 4: GoodRx CAO Thomas Chan Receives RSU Grant

Sentiment:

Statement of Changes in Beneficial Ownership


GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan was granted 54,494 restricted stock units on May 11, 2026.

Summary

  • Thomas Chan, Chief Accounting Officer of GoodRx Holdings, Inc., received a grant of 54,494 restricted stock units (RSUs).
  • Each RSU represents a contingent right to receive one share of Class A common stock.
  • The award is subject to a vesting schedule of 1/12 per quarter, beginning August 15, 2026, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral for the stock price.

Positives

  • The RSU grant serves as a long-term incentive, aligning the interests of the Chief Accounting Officer with those of shareholders.

Negatives

  • The issuance of new equity awards results in potential dilution for existing shareholders.

Risks

  • Vesting is contingent upon the continued service of the reporting person, creating potential retention risk if the executive departs.

Future Outlook

The RSU grant indicates a commitment to executive retention through 2029, based on the 12-quarter vesting schedule.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice for retaining key financial leadership in the healthcare technology sector to ensure long-term alignment with corporate performance.

Comparison to Industry Standards

  • The use of quarterly vesting schedules is consistent with standard executive compensation practices among mid-cap technology and healthcare firms.
  • The grant size is typical for a Chief Accounting Officer role within a company of GoodRx's market capitalization.

Stakeholder Impact

  • Shareholders may experience minor dilution upon the eventual vesting and conversion of these RSUs into Class A common stock.

Next Steps

  • Quarterly vesting of 1/12 of the RSU award beginning August 15, 2026.

Key Dates

DateDescription
05/11/2026Date of RSU grant transaction.
05/12/2026Date of filing.
08/15/2026Initial vesting date for the RSU award.

Keywords

GoodRx, GDRX, Form 4, Insider Transaction, Equity Compensation, Chief Accounting Officer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.